132 related articles for article (PubMed ID: 38483445)
1. Can a combination of probiotics and nutraceuticals help preventing the abemaciclib-related diarrhea in breast cancer patients?
Pacetti U; DI Pierro F; Cazzaniga M; Cavecchia I; Matera M; Bertuccioli A; Zerbinati N; Guasti L; Stani SC
Minerva Gastroenterol (Torino); 2024 Jun; 70(2):242-244. PubMed ID: 38483445
[No Abstract] [Full Text] [Related]
2. In brief: Abemaciclib (Verzenio) for early breast cancer.
Med Lett Drugs Ther; 2021 Dec; 63(1639):199-200. PubMed ID: 35100237
[No Abstract] [Full Text] [Related]
3. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
[TBL] [Abstract][Full Text] [Related]
4. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M; Tokunaga E; Mori J; Tanizawa Y; van der Walt JS; Kawaguchi T; Goetz MP; Toi M
Breast Cancer; 2022 Jan; 29(1):174-184. PubMed ID: 34661821
[TBL] [Abstract][Full Text] [Related]
5. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
6. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2- Early Breast Cancer.
Oncologist; 2021 Feb; 26 Suppl 2(Suppl 2):S5-S6. PubMed ID: 33399254
[TBL] [Abstract][Full Text] [Related]
8. Abemaciclib for the treatment of breast cancer.
Kotake T; Toi M
Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
10. Single-Agent Abemaciclib Active in Breast Cancer.
Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib: First Global Approval.
Kim ES
Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
[No Abstract] [Full Text] [Related]
13. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Petrelli F; Ghidini A; Pedersini R; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Amoroso V; Berruti A; Barni S
Breast Cancer Res Treat; 2019 Apr; 174(3):597-604. PubMed ID: 30659432
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib Shows Promise for Early Breast Cancer.
Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
[TBL] [Abstract][Full Text] [Related]
15. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
[TBL] [Abstract][Full Text] [Related]
16. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino P; Burstein HJ; Lin NU; Krop IE; Winer EP; Schnitt SJ; Hamilton EP; Hurvitz SA; Rugo HS; Curigliano G; Tolaney SM
Ann Oncol; 2022 Mar; 33(3):234-238. PubMed ID: 34942341
[No Abstract] [Full Text] [Related]
17. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
Tarantino P; Jin Q; Mittendorf EA; King TA; Curigliano G; Tolaney SM
Ann Oncol; 2022 Aug; 33(8):845-847. PubMed ID: 35525374
[No Abstract] [Full Text] [Related]
19. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
20. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
